ImmuCell Corporation (NASDAQ:ICCC) and Adial Pharmaceuticals Inc. (NASDAQ:ADIL) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell Corporation	10.99M	3.94	2.32M	-0.42	0.00
Adial Pharmaceuticals Inc.	N/A	0.00	11.63M	-1.87	0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of ImmuCell Corporation and Adial Pharmaceuticals Inc.

Profitability

Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

	Net Margins	Return on Equity	Return on Assets
ImmuCell Corporation	-21.11%	-6.7%	-4.6%
Adial Pharmaceuticals Inc.	0.00%	0%	-775.4%

Liquidity

ImmuCell Corporation has a Current Ratio of 3.2 and a Quick Ratio of 2.1. Competitively, Adial Pharmaceuticals Inc.’s Current Ratio is 16.2 and has 16.2 Quick Ratio. Adial Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than ImmuCell Corporation.

Institutional and Insider Ownership

ImmuCell Corporation and Adial Pharmaceuticals Inc. has shares owned by institutional investors as follows: 14.1% and 2.8%. 6.3% are ImmuCell Corporation’s share owned by insiders. Insiders Comparatively, owned 34.27% of Adial Pharmaceuticals Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
ImmuCell Corporation	-3.63%	-11.15%	-9.35%	7.5%	-5.06%	-0.3%
Adial Pharmaceuticals Inc.	-15.11%	-38.39%	155.3%	11.22%	0%	-34.18%

For the past year ImmuCell Corporation’s stock price has smaller decline than Adial Pharmaceuticals Inc.

Summary

On 6 of the 9 factors ImmuCell Corporation beats Adial Pharmaceuticals Inc.

ImmuCell Corporation develops, acquires, manufactures, and sells products that enhance animal health and productivity of cows for the dairy and beef industries in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; Wipe Out Dairy Wipes, which consist of towelettes that are pre-moistened with a Nisin-based formulation to prepare the teat area of a cow in advance of milking; and California Mastitis Test that could be used for bulk tank and individual cow sample monitoring, as well as to determine which quarter of the udder is mastitic. It is also involved in the development of Mast Out, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and treatments that prevent E. coli K99 and bovine coronavirus, as well as calf scours caused by enteric pathogens. In addition, the company sells various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to distributors and bovine veterinarians, as well as directly to producers. The company was founded in 1982 and is based in Portland, Maine.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.